v3.25.2
Cover
Jun. 23, 2025
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on June 23, 2025 (the “Original Form 8-K”), on June 18, 2025 (the “Closing Date”), Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of Shineco, Inc. (the “Company”), closed an acquisition of 51% of the equity interests in InfiniClone Limited, a company limited by shares incorporated in Hong Kong (“InfiniClone”), pursuant to the share purchase agreement (the “SPA”) dated April 22, 2025 with Dr. Lim Kah Meng, the sole shareholder of InfiniClone (the “Seller”). On or prior to the Closing Date, the closing conditions as set forth in the SPA were satisfied or otherwise waived by the parties thereto, and the Seller has transferred 51% of the equity interests in InfiniClone to Shineco Life Science; therefore, InfiniClone became a direct subsidiary of Shineco Life Science.
Document Period End Date Jun. 23, 2025
Entity File Number 001-37776
Entity Registrant Name SHINECO, INC.
Entity Central Index Key 0001300734
Entity Tax Identification Number 52-2175898
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Room 1707, Block D, Modern City SOHO
Entity Address, Address Line Two No. 88, Jianguo Road
Entity Address, Address Line Three Chaoyang District
Entity Address, City or Town Beijing
Entity Address, Country CN
Entity Address, Postal Zip Code 100022
City Area Code (+86)
Local Phone Number 10-87227366
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SISI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false